Published in Medicine and Law Weekly, June 24th, 2005
The patent describes the composition of AVR118 and methods of manufacturing it.
"Developing a strong worldwide intellectual property estate is critical in the field of biotechnology," said Elma S. Hawkins, president and CEO of Advanced Viral Research Corp. "This is our second patent granted in China for AVR118, thereby providing additional protection for our flagship product."
Currently, ADVR is engaged in a phase II, multicenter, randomized,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.